PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of adrHomeAboutSubmit to JDRJDR
 
Adv Dent Res. 2011 April; 23(1): 45–49.
PMCID: PMC3144040

Candida-Host Interactions in HIV Disease

Implications for Oropharyngeal Candidiasis
Monitoring Editor: Maeve M. Coogan, Tao Xu, Guang-yan Yu, John Greenspan, and Stephen J. Challacombe

Abstract

Oropharyngeal candidiasis (OPC), caused primarily by Candida albicans, is the most common oral infection in HIV+ persons. Although Th1-type CD4+ T cells are the predominant host defense mechanism against OPC, CD8+ T cells and epithelial cells become important when blood CD4+ T cells are reduced below a protective threshold during progression to AIDS. In an early cross-sectional study, OPC+ tissue biopsied from HIV+ persons had an accumulation of activated memory CD8+ T cells at the oral epithelial–lamina propria interface, with reduced expression of the adhesion molecule E-cadherin, suggesting a protective role for CD8+ T cells but a dysfunction in the mucosal migration of the cells. In a subsequent 1-year longitudinal study, OPC patients with high oral Candida colonization (indicative of a preclinical OPC condition), had higher numbers of CD8+ T cells distributed throughout the tissue, with normal E-cadherin expression. In OPC+ patients, where lack of CD8+ T cell migration was associated with reduced E-cadherin, subsequent evaluations following successful treatment of infection revealed normal E-cadherin expression and cellular distribution. Regarding epithelial cell responses, intact oral epithelial cells exhibit fungistatic activity via an acid-labile protein moiety. A proteomic analysis revealed that annexin A1 is a strong candidate for the effector moiety. The current hypothesis is that under reduced CD4+ T cells, HIV+ persons protected from OPC have CD8+ T cells that migrate to the site of a preclinical infection under normal expression of E-cadherin, whereas those with OPC have a transient reduction in E-cadherin that prohibits CD8+ T cells from migrating for effector function. Oral epithelial cells concomitantly function through annexin A1 to keep Candida in a commensal state but can easily be overwhelmed, thereby contributing to susceptibility to OPC.

Keywords: AIDS, Candida albicans, epithelial cells, T cells, mucosal immunity, cytokines

Oropharyngeal candidiasis (OPC) is an opportunistic fungal infection that can involve the hard and soft palate, tongue, buccal mucosa, and floor of the mouth. It primarily presents as white curdlike lesions (pseudomembranous, also known as thrush) or reddened patches (erythematous; Calderone, 2002). OPC is defined as superficial candidiasis with shallow levels of tissue invasion. As a result, chewing and swallowing can be difficult. Infections can be acute or recurrent, and they are common in immunocompromised patients—especially, those infected with the human immunodeficiency virus (HIV; reviewed in Fidel, 2002). OPC is one of the first clinical signs of underlying HIV infection, and it will occur in 50% to 95% of all HIV+ persons sometime during their progression to AIDS (Rabeneck et al., 1993). OPC is also a common manifestation of chronic mucocutaneous candidiasis, and it occurs in patients with lymphoma, in those undergoing steroid therapy, and in transplant recipients (reviewed in Deslauriers et al., 1997; Calderone, 2002). Although OPC will occur under several immunocompromising conditions, it appears to be much more common in HIV+ persons than in the other named conditions. The use of highly active antiretroviral therapy in those with HIV has significantly reduced the incidence of OPC (Palella et al., 1998). This is postulated to be due to increased immune responsiveness as well as direct action on the organism by protease inhibitors (Cassone et al., 1999; Gruber et al., 1999; Calderone and Fonzi, 2001).

OPC is caused primarily by Candida albicans, a ubiquitous dimorphic fungal organism that is part of the normal microflora of the gastrointestinal and reproductive tracts of healthy individuals. For asymptomatic carriers, the approximate rate of oral yeast carriage in HIV-negative persons is 50% to 60%, with C. albicans present in 85% of isolates recovered (Glick and Siegel, 1999). In HIV+ individuals, the asymptomatic colonization rate is higher, approaching 76% (Leigh et al., 1998; Wozniak et al., 2002). Colonization with C. albicans is assumed to be responsible for acquired immune responsiveness. Anti-Candida antibodies—circulating immunoglobulin G and mucosal immunoglobulins A and G—can be detected in most healthy individuals (Witkin et al., 1988, 1989; Regulez et al., 1994; Wozniak et al., 2002). Moreover, greater than 80% of healthy persons have positive cutaneous skin test reactivity to Candida antigen, and peripheral blood lymphocytes from more than 90% of healthy individuals proliferate in vitro to Candida antigen (Kirkpatrick et al., 1971; Mathur et al., 1977; Fidel et al., 1993; Deslauriers et al., 1997). These acquired host responses in conjunction with innate resistance (i.e., epithelial cells, polymorphonuclear leukocytes and macrophages) presumably play a significant role in restricting C. albicans to mucosal surfaces in an asymptomatic commensal state. But under immunocompromised conditions, C. albicans—along with its virulence factors, such as proteases, morphologic transition, phenotypic switching, biofilm formation—can convert into an opportunistic pathogen with significant morbidity. The following section offers a brief review of published data regarding host defenses present in those with and without OPC relative to T cells, cytokines, and epithelial cells; it follows with new, unpublished data from the Fidel laboratory, as presented at the Sixth World Workshop on Oral Health and Disease in AIDS, which together provide potential explanations for the resistance and susceptibility to OPC.

Host Defense Against OPC

Previously Reported Data

The majority of data suggest that CD4+ Th1-type cells are critical for host defense against OPC. Clinically, OPC is most common in HIV+ persons when CD4+ cell numbers drop below 200 cells/µL (Rabeneck et al., 1993; Nielsen et al., 1994; Schuman et al., 1998; Greenspan et al., 2000). In in vitro immune analyses, peripheral blood mononuclear cells from most individuals, including HIV+ persons, respond to Candida antigens with Th1-type cytokines (Kunkl et al., 1998; Leigh et al., 2001). These results suggest that the Candida-specific T cells were not becoming defective with immunosuppression but that a threshold number of CD4+ T cells is required to protect the oral cavity against infection by this commensal organism. Below this threshold number of cells, other systemic and/or local immune mechanisms must function exclusively. Resistance and susceptibility to OPC then depends on the status of these alternative immune mechanisms.

Several aspects of local immunity have been clinically evaluated. In support of the Th1/Th2 dichotomy concept, Leigh et al. (1998) reported that HIV individuals had Th1/Th0 cytokines in their saliva, whereas HIV+ individuals had primarily Th2-type cytokines, which was more profound in those patients with OPC. Lymphocytes have also been examined in the OPC lesions. Although both CD4+ and CD8+ cells have been identified (Romagnoli et al., 1997), we reported an accumulation of CD8+ T cells at a considerable distance from Candida, superficially located at the outer epithelium (Myers et al., 2003), thus suggesting a role for CD8+ T cells against infection but with a potential problem in cell trafficking or the microenvironment that promotes susceptibility to OPC. Increases in mRNA for several CD8 cell–associated cytokines (IL-2 and IL-15) and chemokines (IP-10, RANTES, and MCP-1; Lilly et al., 2004) supported a role for reactivity by CD8 T cells. A murine AIDS model showed a rate of 30% recurrent OPC, with a predominance of CD8+ T cells recruited into the oral tissues (Deslauriers et al., 1997). The tissue-associated CD8+ T cells primarily possess the αβ T-cell receptor (McNulty et al., 2005). The CD8 T cells present in the lesions are activated memory T cells, as evidenced by cell surface activation markers (CD69, CD45R0) that are transitioning between central and effector memory status (CD27Hi, CCR7Lo, CD62LLo; Leigh et al., 2006). Hence, the CD8 T cells appear as normal activated memory cells recruited into the oral mucosa from the periphery but inhibited from migrating further through the mucosa to the outer epithelium.

The issue of cellular migration was addressed through the study of homing receptor/adhesion molecules and chemokine receptors. Chemokine receptor expression was similar in HIV+ OPC+ persons and HIV+ OPC persons (Lilly et al., 2006). Cellular migration is controlled by chemokine receptors as well as cellular heterodimer homing receptors (integrins) and reciprocal tissue-associated adhesion molecules. Some homing receptor–adhesion molecule interactions (α4β7/MAdCAM, α4β1/VCAM-1) govern migration of cells out of blood and into mucosal tissues, whereas others govern migration through mucosal tissues (αeβ7/E-cadherin). The CD8+ T cells present in OPC and OPC+ tissue had positive integrin expression in varying combinations but no discernible difference in OPC versus OPC+ tissue. In contrast, MAdCAM expression was significantly increased in OPC+ tissue, in support of the increased presence of T cells, whereas E-cadherin was significantly decreased in OPC+ tissue (McNulty et al., 2005). The reduced E-cadherin provides an explanation for the inability of the CD8+ T cells to migrate to the outer epithelium and so represents a putative dysfunction in those with OPC, lending to the susceptibility to OPC.

Humoral immunity does not appear to play a role in protection against or susceptibility to OPC. There is no evidence to date that a deficiency in Candida-specific antibodies is present in HIV+ persons that could account for the increased prevalence of OPC (Wray et al., 1990; Millon et al., 2001; Wozniak et al., 2002).

Innate cellular defenses also play a role in host defense. Our laboratory has studied the role of epithelial cells for a number of years. These studies have shown that oral epithelial cells can inhibit up to 80% of the Candida growth in vitro by a fungistatic mechanism via cell contact by intact but not necessarily live epithelial cells through an acid-labile protein receptor (Steele et al., 1999, 2000, 2001; Nomanbhoy et al., 2002; Yano et al., 2005). Analysis of oral epithelial cells in HIV+ persons showed significantly reduced activity by cells from patients with OPC compared to that from patients without OPC, providing support as an innate protective mechanism against infection (Steele et al., 2000). Additionally, epithelial cells produce cytokines and chemokines in response to Candida, which may contribute to the innate and/or adaptive immune response (Rouabhia et al., 2002; Schaller et al., 2002; Steele and Fidel, Jr., 2002; Dongari-Bagtzoglou and Kashleva, 2003a, 2003b).

On the basis of these data, we propose that several secondary lines of defense are important for protection against OPC when the primary defense by CD4+ cells are below the protective threshold. These include CD8 T cells and oral epithelial cells. The Figure illustrates a diagram depicting this hypothesis. In HIV+ persons with < 200 CD4 cells/µL and OPC, it is postulated that although the CD4+ T cells are below the protective threshold, epithelial cells have activity against Candida to hold it “in check,” and CD8+ T cells are able to migrate to the outer epithelium to aid in protection. However, in those susceptible to OPC, the CD8+ T cells are inhibited from migrating to the outer epithelium because of reduced E-cadherin with reduced levels of epithelial cell anti-Candida activity, resulting in bouts of OPC.

Fig.
Proposed immune function of the oral mucosa in HIV+ individuals with and without oropharyngeal candidiasis (OPC) and < 200 CD4 cells/µL. Left frame depicts the protective mechanisms associated with the HIV+ OPC individual colonized ...

New Findings

Based on the cross-sectional data with the CD8 T cells and E-cadherin (reviewed in Fidel, 2006), the next important step was to conduct a longitudinal analysis of CD8+ T cells in the tissue of those HIV+ patients who have not acquired OPC, who have had sporadic cases of OPC, or who have recurrent OPC. The objective was to confirm the cross-sectional findings and determine whether the reduction in E-cadherin in those with OPC was permanent or transient. Oral swabs were taken every 2 weeks and biopsies every 2 months to track changes in the CD8+ T cells and adhesion molecule expression before, during, and after OPC episodes. In total, the results to date have shown that although OPC patients with low oral fungal burden revealed an unremarkable presence of CD8+ T cells and normal E-cadherin expression, OPC patients who had increased oral Candida colonization (indicative of a potential preclinical OPC condition) had higher numbers of CD8+ T cells throughout the tissue with normal E-cadherin expression. In patients with reduced E-cadherin expression and an acute episode of OPC where CD8+ T cells were accumulated at the epithelial–lamina propria interface, evaluation of E-cadherin following successful antifungal treatment revealed a return to normal expression. These results suggest that under conditions of CD4+ T-cell deficiency, CD8+ T cells typically migrate to the site of a preclinical infection via normal expression of E-cadherin and reduced E-cadherin expression in those with OPC is not permanent. The reduction in E-cadherin that we have observed in patients with OPC is consistent with 2 independent studies showing that Candida can cleave or degrade E-cadherin (Frank and Hostetter, 2007; Villar et al., 2007). Hence, the reduction in E-cadherin may be a virulence mechanism for Candida that, when adherent to the epithelium, promotes subsequent invasion. We postulate that increases in Candida levels lead to increased degradation of E-cadherin, which creates an environment more conducive to infection and invasion and the onset of OPC.

The metabolic state of the epithelial cells is important in understanding the interaction of Candida with E-cadherin, as is the cellular localization of the epithelial cells. Phan et al. (2007) showed that an adhesin (Als3) on C. albicans hyphae can bind E-cadherin on metabolically active epithelial cells, which induces endocytosis. Thus, it appears that Candida can either degrade or use E-cadherin. We hypothesize that these 2 conditions can and do occur depending on the location of the epithelial cells. If Candida gains access to basal epithelial cells that are metabolically active, it will use E-cadherin to gain intracellular access through endocytosis. But if Candida remains on the apical epithelium, it will likely degrade E-cadherin to occupy and superficially attach to the outer epithelium rather than be released from the epithelium inside metabolically inactive sloughing cells. In any event, it appears that Candida has the ability to modulate E-cadherin rather than become modulated by a host-dependent mechanism (transient or permanent). If so, immunotherapeutic strategies directed toward restoring normal E-cadherin expression would allow CD8+ T cells to migrate to the outer epithelium, where antifungal effector activity would be critical to reducing the incidence of OPC in susceptible populations. Current studies are focusing on the mechanism of action by CD8+ T cells.

In other studies, the objective was to identify the antifungal effector moiety on oral epithelial cells; accordingly, the acid treatment that abrogates the antifungal activity was used. The strategy involved extracting surface-associated glycoproteins from the epithelial cells treated with and without periodic acid. The extracted glycoproteins were then incubated with Candida, and any bound epithelial proteins were then eluted from Candida and separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Because this method could result in contamination of samples with Candida cell surface–associated proteins, we labeled the epithelial cell surface proteins with biotin before the acid treatment and protein extraction, which allowed for the use of Western blots to focus only on epithelial cell proteins. Results revealed 2 protein bands (approximately 33 and 45 kDa) eluted from Candida blastoconidia or hyphae that are present in phosphate buffered saline–treated cells but not periodic acid–treated epithelial cells.

Proteomic analysis was then conducted on the unique bands from phosphate buffered saline–treated cells. Results showed that the 45-kDa protein for the phosphate buffered saline–treated cells was an actin molecule, whereas the 33-kDa protein was annexin A1. The latter is a viable candidate for the effector molecule because it functions through signaling cascades to inhibit cellular processes, including growth (Croxtall et al., 2003; Liu et al., 2007). Further studies showed that annexin A1 but not actin (as expected) was present on the epithelial cell surface. Functional studies are underway to confirm the role of annexin A1 and elucidate the mechanism of action.

Finally, the extracted epithelial cell surface proteins were evaluated for antifungal activity. Results demonstrated that proteins extracted from phosphate buffered saline–treated cells but not periodic acid–treated cells were capable of inhibiting the growth of Candida, similar to intact epithelial cells. These data are consistent with the fact that live epithelial cells are not required despite the need for cell contact.

Conclusions

Our data suggest that protection against OPC involves primary and secondary host defense mechanisms. The primary and most critical host defense against OPC involves CD4+ T cells. However, the role of CD4+ T cells is lessened as cell counts fall in association with the progression to AIDS. During CD4+ T-cell deficiency, secondary host defenses become critical (i.e., primary) in providing protection against OPC. These secondary defenses include cytokines in saliva that can promote protection (Th1 type or proinflammatory), the epithelial cell anti-Candida activity, and tissue-associated CD8+ T cells with the appropriate homing receptors and adhesion molecules that allow them to maximize their migration and effector function. Progress has been made in elucidating the mechanism of the epithelial cell effector activity. The lack of a requirement for live metabolically active epithelial cells suggests that the growth inhibitory signal (or signals) is mediated by cascades in Candida and not the epithelial cells as part of a sophisticated symbiosis where Candida sacrifices growth for protection against killing by some other immune activity (immune evasion). In regard to the mechanism of the putative CD8 T-cell effector activity, standard cytotoxic T-lymphocyte activity would not be predicted. Rather, we postulate that the effector activity of CD8 T cells occurs via a non-MHC-restricted mechanism similar to that reported for murine CD8+ T cells cultured with IL-2 (Beno and Mathews, 1992; Beno et al., 1995). A similar mechanism was also reported against HIV (Stranford et al., 1999; Mackewicz et al., 2000). Interestingly, IL-2 mRNA has been shown to be present in the tissue of OPC HIV+ individuals and increased in OPC+ HIV+ patients (Lilly et al., 2004). Thus, if the CD8+ T cells were present and the E-cadherin could promote adequate migration of the CD8+ activated memory T cells, an effective response against OPC could occur despite other factors that promote OPC. That E-cadherin is not permanently reduced in those susceptible to OPC, as evidenced by the longitudinal analyses, suggests that immunotherapeutic strategies can be developed to enhance E-cadherin that would in turn reduce OPC in vulnerable populations such as HIV+ patients.

Taken together, our previous and current work continue to support the overall hypothesis that CD8+ T cells and oral epithelial cells represent important anti-Candida oral host defenses when CD4+ T cells drop below protective levels and that the oral microenvironment can be enhanced by immunotherapeutic strategies to optimize their protective capacity.

Footnotes

This work was supported by Public Health Service grant DE-12178 from the National Institute of Dental and Craniofacial Research from the National Institutes of Health and in part by the Louisiana Vaccine Center and the South Louisiana Institute for Infectious Disease Research, sponsored by the Louisiana Board of Regents.

References

  • Beno DW, Mathews HL. (1992). Growth inhibition of Candida albicans by interleukin-2-activated splenocytes. Infect Immun 60:853-863. [PMC free article] [PubMed]
  • Beno DW, Stover AG, Mathews HL. (1995). Growth inhibition of Candida albicans hyphae by CD8+ lymphocytes. J Immunol 154:5273-5281. [PubMed]
  • Calderone RA, editor. , editor. (2002). Candida and Candidiasis. Washington, DC: ASM Press.
  • Calderone RA, Fonzi WA. (2001). Virulence factors of Candida albicans. Trends Microbiol 9:327-335. [PubMed]
  • Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. (1999). In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 180:448-453. [PubMed]
  • Croxtall JD, Gilroy DW, Solito E, Choudhury Q, Ward BJ, Buckingham JC, et al. (2003). Attenuation of glucocorticoid functions in an Anx-A1-/- cell line. Biochem J 371(pt 3):927-935. [PubMed]
  • Deslauriers N, Cote L, Montplaisir S, De Repentigny L. (1997). Oral carriage of Candida albicans in murine AIDS. Infect Immun 65:661-667. [PMC free article] [PubMed]
  • Dongari-Bagtzoglou A, Kashleva H. (2003a). Candida albicans triggers interleukin-8 by oral epithelial cells. Microb Pathog 34:169-177. [PubMed]
  • Dongari-Bagtzoglou A, Kashleva H. (2003b). Granulocyte-macrophage colony-stimulating factor responses of oral epithelial cells to Candida albicans . Oral Microbiol Immunol 18:165-170. [PubMed]
  • Fidel PL., Jr (2002). Distinct protective host defenses against oral and vaginal candidiasis. Med Mycol 40:359-375. [PubMed]
  • Fidel PL. (2006). Candida-host interactions in HIV disease: relationships in oropharyngeal candidiasis. Adv Dent Res 19:80-84. [PubMed]
  • Fidel PL, Jr, Lynch ME, Redondo-Lopez V, Sobel JD, Robinson R. (1993). Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis (RVVC). J Infect Dis 168:1458-1465. [PubMed]
  • Frank CF, Hostetter MK. (2007). Cleavage of E-cadherin: a mechanism for disruption of the intestinal epithelial barrier by Candida albicans . Transl Res 149:211-222. [PubMed]
  • Glick M, Siegel MA. (1999). Viral and fungal infections of the oral cavity in immunocompetent patients. Infect Dis Clin North Am 13:817-831. [PubMed]
  • Greenspan D, Komaroff E, Redford M, Phelan JA, Navazesh M, Alves ME, et al. (2000). Oral mucosal lesions and HIV viral load in the Women’s Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 25:44-50. [PubMed]
  • Gruber A, Speth C, Lukasser-Vogl E, Zangerle R, Borg-von Zepelin M, Dierich MP, et al. (1999). Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 41:227-234. [PubMed]
  • Kirkpatrick CH, Rich RR, Bennett JE. (1971). Chronic mucocutaneous candidiasis: model building in cellular immunity. Ann Intern Med 74:955-978. [PubMed]
  • Kunkl A, Mortara L, Valle MT, Fenoglio D, Teranova MP, Megiovanni AM, et al. (1998). Recognition of antigenic clusters of Candida albicans by T lymphocytes from human immunodeficiency virus-infected persons. J Infect Dis 178:488-496. [PubMed]
  • Leigh JE, Barousse M, Swoboda RK, Myers T, Hager S, Wolf NA, et al. (2001). Candida-specific systemic cell-mediated immune reactivities in HIV-infected persons with and without mucosal candidiasis. J Infect Dis 183:277-285. [PubMed]
  • Leigh JE, McNulty KM, Fidel PL., Jr (2006). Characterization of the immune status of CD8+ T cells in oral lesions of human immunodeficiency virus-infected persons with oropharyngeal candidiasis. Clin Vaccine Immunol 13:678-683. [PMC free article] [PubMed]
  • Leigh JE, Steele C, Wormley FL, Jr, Luo W, Clark RA, Gallaher W, et al. (1998). Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: a pilot study in HIV-positive individuals with oropharyngeal candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol 19:373-380. [PubMed]
  • Lilly E, Hart DJ, Leigh JE, Hager S, McNulty KM, Mercante DE, et al. (2004). Tissue-associated cytokine expression in HIV-positive persons with oropharyngeal candidiasis. J Infect Dis 190:605-612. [PubMed]
  • Lilly EA, Leigh JE, McNulty KM, Joseph SH, Mercante DE, Fidel PL., Jr (2006). Chemokine receptor expression in HIV-positive persons with oropharyngeal candidiasis. Oral Dis 12:493-499. [PubMed]
  • Liu N, Zhang YP, Han S, Pei J, Xu LY, Lu P, et al. (2007). Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury. J Neuropathol Exp Neurol 66:932-943. [PubMed]
  • Mackewicz CE, Patterson BK, Lee SA, Levy JA. (2000). CD8(+) cell noncytotoxic anti-human immunodeficiency virus response inhibits expression of viral RNA but not reverse transcription or provirus integration. J Gen Virol 81(pt 5):1261-1264. [PubMed]
  • Mathur S, Koistinen GV, Horger EO, 3rd, Mahvi TA, Fudenberg HH. (1977). Humoral immunity in vaginal candidiasis. Infect Immun 15:287-294. [PMC free article] [PubMed]
  • McNulty KM, Plianrungsi J, Leigh JE, Mercante D, Fidel PL., Jr (2005). Characterization of CD8+ T-cells and microenvironment in oral lesions of HIV-infected persons with oropharyngeal candidiasis. Infect Immun 73:3659-3667. [PMC free article] [PubMed]
  • Millon L, Drobacheff C, Piarroux R, Monod M, Reboux G, Laurent R, et al. (2001). Longitudinal study of anti–Candida albicans mucosal immunity against aspartic proteinases in HIV-infected patients. J Acquir Immune Defic Syndr 26:137-144. [PubMed]
  • Myers TA, Leigh JE, Arribas AR, Hager S, Clark R, Lilly E, et al. (2003). Immunohistochemical evaluation of T cells in oral lesions from human immunodeficiency virus-positive persons with oropharyngeal candidiasis. Infect Immun 71:956-963. [PMC free article] [PubMed]
  • Nielsen H, Bentsen KD, Højtved L, Willemoes EH, Scheutz F, Schiødt M, et al. (1994). Oral candidiasis and immune status of HIV-infected patients. J Oral Pathol Med 23:140-143. [PubMed]
  • Nomanbhoy F, Steele C, Yano J, Fidel PL., Jr (2002). Vaginal and oral epithelial cell anti-Candida activity. Infect Immun 70:7081-7088. [PMC free article] [PubMed]
  • Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 338:853-860. [PubMed]
  • Phan QT, Myers CL, Fu Y, Sheppard DC, Yeaman MR, Welch WH, et al. (2007). Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 5:e64. [PMC free article] [PubMed]
  • Rabeneck L, Crane MM, Risser JM, Lacke CE, Wray NP. (1993). A simple clinical staging system that predicts progression to AIDS using CD4 count, oral thrush, and night sweats. J Gen Intern Med 8:5-9. [PubMed]
  • Regulez P, Garcia Fernandez JF, Moragues MD, Schneider J, Quindos G, Ponton J. (1994). Detection of anti–Candida albicans IgE antibodies in vaginal washes from patients with acute vulvovaginal candidiasis. Gynecol Obstet Invest 37:110-114. [PubMed]
  • Romagnoli P, Pimpinelli N, Mori M, Reichart PA, Eversole LR, Ficarra G. (1997). Immunocompetent cells in oral candidiasis of HIV-infected patients: an immunohistochemical and electron microscopical study. Oral Dis 3:99-105. [PubMed]
  • Rouabhia M, Ross G, Page N, Chakir J. (2002). Interleukin-18 and gamma interferon production by oral epithelial cells in response to exposure to Candida albicans or lipopolysaccharide stimulation. Infect Immun 70:7073-7080. [PMC free article] [PubMed]
  • Schaller M, Mailhammer R, Grassl G, Sander CA, Hube B, Korting HC. (2002). Infection of human oral epithelia with Candida species induces cytokine expression correlated to the degree of virulence. J Invest Dermatol 118:652-657. [PubMed]
  • Schuman P, Ohmit S, Sobel JD, Mayer KH, Greene V, Rompalo A, et al. (1998). Oral lesions among women living with or at risk for HIV infection. Am J Med 104:559-564. [PubMed]
  • Steele C, Fidel PL., Jr (2002). Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans . Infect Immun 70:577-583. [PMC free article] [PubMed]
  • Steele C, Leigh J, Swoboda R, Fidel PL., Jr (2000). Growth inhibition of Candida by human oral epithelial cells. J Infect Dis 182:1479-1485. [PubMed]
  • Steele C, Leigh J, Swoboda R, Ozenci H, Fidel PL., Jr (2001). Potential role for a carbohydrate moiety in anti-Candida activity of human oral epithelial cells. Infect Immun 69:7091-7099. [PMC free article] [PubMed]
  • Steele C, Ozenci H, Luo W, Scott M, Fidel PL., Jr (1999). Growth inhibition of Candida albicans by vaginal cells from naive mice. Med Mycol 37:251-259. [PubMed]
  • Stranford SA, Skurnick J, Louria D, Osmond D, Chang SY, Sninsky J, et al. (1999). Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci U S A 96:1030-1035. [PubMed]
  • Villar CC, Kashleva H, Nobile CJ, Mitchell AP, Dongari-Bagtzoglou A. (2007). Mucosal tissue invasion by Candida albicans is associated with E-cadherin degradation, mediated by transcription factor Rim101p and Protease Sap5p. Infect Immun 75:2126-2135. [PMC free article] [PubMed]
  • Witkin SS, Jeremias J, Ledger WJ. (1988). A localized vaginal allergic response in women with recurrent vaginitis. J Allergy Clin Immunol 81:412-416. [PubMed]
  • Witkin SS, Jeremias J, Ledger WJ. (1989). Vaginal eosinophils and IgE antibodies to Candida albicans in women with recurrent vaginitis. J Med Vet Mycol 27:57-58. [PubMed]
  • Wozniak KL, Leigh JE, Hager S, Swoboda RK, Fidel PL., Jr (2002). A comprehensive study of Candida-specific antibodies in saliva of human immunodeficiency virus-positive individuals with oropharyngeal candidiasis. J Infect Dis 185:1269-1276. [PubMed]
  • Wray D, Felix DH, Cumming CG. (1990). Alteration of humoral responses to Candida in HIV infection. Brit Dent J 168:326-329. [PubMed]
  • Yano J, Lilly E, Steele C, Fortenberry D, Fidel PL., Jr (2005). Oral and vaginal epithelial cell anti-Candida activity is acid-labile and does not require live epithelial cells. Oral Microbiol Immunol 20:199-205. [PMC free article] [PubMed]

Articles from Advances in Dental Research are provided here courtesy of International and American Associations for Dental Research